Neurofibromatosis type 2 (NF2) is an autosomal dominant disorder characterized by the development of multiple tumors in the central nervous system, most notably schwannomas and meningiomas. Mutational inactivation of the NF2 gene encoding the protein Merlin is found in most sporadic and inherited schwannomas, but the molecular mechanisms underlying neoplastic changes in schwannoma cells remain unclear. We report here that Nf2-deficient cells display elevated expression levels of key enzymes involved in lipogenesis and that this upregulation is caused by increased activity of Torc1. Inhibition or knockdown of fatty acid synthase (FASN), the enzyme that catalyzes the formation of palmitic acid from malonyl-CoA, drove NF2-deficient cells into apoptosis. Treatment of NF2-mutant cells with agents that inhibit the production of malonyl-CoA reduced their sensitivity to FASN inhibitors. Collectively, these results suggest that the altered lipid metabolism found in NF2-mutant cells renders them sensitive to elevated levels of malonyl-CoA, as occurs following blockade of fatty acid synthase, suggesting new targeted strategies in the treatment of NF2-deficient tumors.
Introduction
Neurofibromatosis type 2 (NF2) is an autosomal dominant cancer predisposition syndrome that occurs due to inactivating mutations in the NF2 gene. NF2 is characterized by formation of multiple low grade tumors along the peripheral nerves and in the central nervous system (1) , and associated with disease manifestations that include benign schwannomas (including bilateral vestibular schwannomas, the hallmark of the disease), meningiomas, and ependymomas. Despite the benign nature of these lesions, NF2 is often fatal due to development of inoperable intracranial tumors. In addition, somatic mutations in the NF2 gene also contribute to malignant mesotheliomas and other tumors (2) . To date there is no effective pharmacotherapy for NF2 and the morbidity and mortality of this inherited disorder remains high.
The NF2 gene product, merlin, is a member of the ezrin-moesin-radixin protein family and functions to regulate cell adhesion via receptor tyrosine kinases and integrins (3-7), proliferative and survival signaling via enzymes such as Rac, PAK, AKT, FAK, and MTOR (8) (9) (10) (11) , and to suppress tumorigenesis via inhibition of the E3 ubiquitin ligase CRL4/DCAF1 complex (12) . In addition, Merlin signaling may also impact the MST/YAP contact inhibition signaling pathway (13) . Loss of NF2 gene leads to inability of cells to form stable cell:cell junctions (14) , and NF2-deficient cells do not show contact growth inhibition (4, 14) . Conversely, Merlin overexpression blocks proliferation (15) .
Currently, three targeted therapeutic approaches are being investigated for potential use in NF2:
angiogenesis inhibitors such as bevacizumab (16, 17) , EGFR inhibitors such as erlotinib and lapatinib (18) , and MTOR inhibitors such as sirolimus and everolimus (19) . While the use of such targeted agents has shown promise in early trials, the redundancy of proliferative, survival, and motility signaling cascades in Merlin-null cells suggests a need to identify additional therapeutic concepts and targets in this disorder.
Recently, there has been revived interest in targeting metabolic enzymes in various malignancies.
Most of these efforts have attempted to exploit unique aspects of sugar metabolism in cancer, the so-called Warburg effect. However, cancer cells also require large amounts of lipid for membrane biosynthesis, energy, and signal transduction and such lipids are supplied by de novo fatty acid synthesis (20) . Accordingly, enzymes involved in fatty acid metabolism, such as fatty acid synthase (FASN), are commonly upregulated in cancer cells, and inhibiting FASN or other enzymes involved in lipogenesis can induce apoptosis in such cells (21, 22) . These data show that enzymes involved in lipid metabolism are potential therapeutic targets against cancers.
In this report, we used Nf2-deficient vs. WT cells to screen for metabolic changes caused by Nf2 gene loss. We found that Nf2-deficient fibroblasts and Schwann cells display a variety of metabolic derangements involving lipid metabolism, in particular, a significant elevation of fatty acid levels. Further studies showed that Nf2-deficient cells are selectively sensitive to inhibitors of fatty acid synthase (FASN). We report that siRNA or small molecule inhibitors of FASN are toxic to Nf2-deficient cells, and that this toxicity appears to be related to a build up of proapoptotic metabolic intermediates, in particular malonyl-CoA. Our findings define a new aspect of NF2 pathobiology that could be used to identify therapeutic agents in this syndrome.
Methods
Plasmids, antibodies, and reagents. pBabe-NF2 was obtained from Addgene. Anti-Fasn siRNA (M-040091-01-0005), anti-Acaca siRNA (M-063938-01-0005), anti-Mtor (M-065427-00-0005), anti-Rptor (M-058754-01-0005), anti-Rictor (M-064598-01-0005) and non-silencing (D-001206-13-05) siRNA were purchased from Dharmacon. Individual siRNAs against Mtor (SASI_Mm01-00164496 and -00164492), Rictor (-00137732 and -00137730), Rptor (-00055298 and -00334580), Fasn (-00177858 and -00177854), Acaca (-0011590 and -00115905), and Mlycd (-00028572 and -00028576) were purchased from Sigma-Aldrich. Anti-Merlin antibodies were purchased from Abcam (#ab88957). Lipid synthesis and metabolism antibody kit (includes anti-Fasn, -phospho ACC, -ACC, -Lipin1, -ACLY, -phospho ACLY, -ACSL1, and -ACECS1 antibodies), and anti-Casp3 antibodies were purchased from Cell Signaling Technology. Anti-SREBP1 antibodies were purchased from Santa Cruz Biotechnology. Anti-GAPDH antibodies were purchased from EMD-Millipore.
Cerulenin, C75, luteolin, 5-(tetradecyloxy)-2-furoic acid (TOFA) and 5-iodotubercidin were purchased from Enzo Life Sciences. GSK2194069, dimethylsulfoxyde (DMSO), staurosporin, sodium palmitate, 70% perchloric acid, ammonium formate, acetonitrile, acetyl-coenzyme A lithium salt, malonyl coenzyme A lithium salt, propionyl-coenzyme A lithium salt, and poly-Llysine were purchased from Sigma-Aldrich.
Cell culture. DMEM, DMEM/F12, PBS, N2 supplement, 0.05% trypsin, and Alamar Blue were purchased from Life Technologies. Fetal bovine serum was purchased from Atlanta Biologicals, heregulin-1 from R&D Systems, forskolin and laminin from EMD Millipore, and the WST-1 assay kit from Clontech. were fixed using 4% paraformaldehyde (PFA) and permeablised using 0.2% Triton X-100 before being blocked using 10% normal goat serum. Cells were then incubated with primary antibodies overnight at 4° C at a concentration of 1:100 in 1%BSA Phosphate-buffered saline (PBS). AntiKi67 (Dako) was used as a marker or proliferating cells and anti-cleaved caspase-3 (Cell Signalling Technologies) was used as a marker or cells undergoing apoptosis. AlexaFluorTM secondary antibodies goat-anti mouse 594 and goat-anti rabbit 488 were used and DAPI applied as a nuclear stain.
Confocal Microscopy: Multitrack imaging was performed using a Zeiss Confocal LSM510.
Proliferation and survival assays which were carried out using a 20x air objective. The appropriate Zeiss image manipulation software (ZEN) was used for editing.
Transfections were done by electroporation using Neon transfection system (Life Technologies, Grand Island, NY) according to manufacturer's protocol. Transfections were done in 100 L tips. For DNA transfections final concentration of 5 g per reaction was used. For RNA transfections final concentration of 100 nM was used.
Immunoblotting. Cells were lysed with RIPA (1% Triton-X100; 10% glycerol; 50 mM HEPES, pH 7.4; 150 mM NaCl; 1.5 mM MgCl2, 1 mM EGTA, 1 mM EDTA, 0.1% SDS, 10 mM phenylmethylsulphonyl-fluoride; aprotinin 10 µg/mL, leupeptin 10µg/mL, pepstatin 10 µg/mL, qPCR. Cells were grown in serum-free media in 6-cm plates until confluent, and total RNA was extracted using RNeasy Minikit (Qiagen, Valencia, CA). Quantitative RT-PCR reactions were performed using TaqMan probes and primers designed by the manufacturer, using an ABI PRISM 7700 detection system (Applied Biosystems, Foster City, CA). Results were analyzed using relative standard curve method. For Acacb comparative Ct method was used. The average (Table 2) , consistent with increased energy demand in these cells (24) (25) (26) . An increase in vitamins and cofactors levels was also observed (Table S1) , especially, nicotinate metabolites involved in electron chain transport (NAD + , NADH, and NADP) and pantothenate metabolites involved in coenzyme A turnover, consistent with an increased energy production in Nf2-deficient cell lines (27) . In addition, the level of metabolites associated with glycolysis was decreased in both FH912 Schwann cells and Nf2 -/-MEFs (Table 1) , as well as a drop in amino acids, including particularly glutamine metabolites (Table S2) , suggesting upregulated glutaminolysis supporting the more active TCA cycle. The most profound metabolic alteration, however, was the marked elevation of fatty acid levels in both FH912 cells and Nf2 -/-MEFs ( Table 2) . (Fig. 1A) . The schwannoma cell lines SC4-9 and RT4 were also sensitive to similar levels of this compound. Re-expression of Merlin in SC4-9 cells rendered these cells insensitive to cerulenin (almost two-fold difference in IC50 values, p < 0.0001) (Fig. 1B) Luteolin (25) . In each case, loss of Nf2 was associated with higher sensitivity to the FASN inhibitors ( Fig. 1D-1F ).
Loss of the
We next performed xenograft studies on female nu/nu mice using SC4-9 cells. Xenografts were placed in the flanks and the mice were treated with cerulenin (30 mg/kg/day), GSK2194069 (3 mg/kg/day), or vehicle for 28 days. As shown in Figure 1G , treatment with GSK2194069 caused a nearly two-fold reduction in tumor growth (p=0.0049), and cerulenin treatment caused a threefold reduction (p=0.00039), consistent with the notion that inhibiting FASN represents a potentially effective strategy for NF2. At the dose given mice tolerated treatment well and did not experience weight loss or skin dryness. Remarkably, much lower doses of cerulenin (2 mg/kg/day) also effectively slowed down the tumour growth ( Figure S1D ). As has been reported previously (30) treatment with cerulenin was associated with a significant FASN expression decrease detected by immunoblotting of the tumor samples (Fig. S1D) . (Fig. 2А) . Remarkably, normal
Schwann cells turned to be virtually insensitive to GSK2194069 (Fig. 2А) . Primary human meningioma cells also displayed similar sensitivity to the compounds, while normal human meningeal cells (HMC) were much less sensitive (IC50 2.77 ± 1.57 M vs 28.79 ± 15.86 M, respectively) (Fig. 2B) .
Reversal of the cerulenin effect by blockade of malonyl-CoA synthesis. FASN catalyzes production of palmitic acid, an essential building block for long-chain fatty acids (28, 31) . By inhibiting FASN, cerulenin blocks the malonyl-CoA condensation step of fatty acid synthesis, causing a deficit in palmitic acid as well as an accumulation of malonyl-CoA (26, (32) (33) (34) (35) . The toxicity of malonyl-CoA in cancer cells is thought to be mediated by inhibition of carnitine palmitoyltransferase 1-regulated fatty acid β-oxidation, in turn promoting the accumulation of the sphingolipid ceramide followed by the induction of the pro-apoptotic genes such as BNIP3, TRAIL and DAPK2, effectors in the ceramide-mediated apoptotic pathway (36) .
To evaluate the possibility that cerulenin effects in Nf2 -/-cells might be related to reduced palmitic acid availability, we supplemented the growth media of Nf2 -/-and Nf2 f/f cells with palmitic acid. This addition did not reverse the toxicity of cerulenin (Fig. 3A) . We next considered whether lack of fatty acid precursors or accumulation of malonyl-CoA might promote cell death in cerulenin-treated Nf2 -/-cells. We therefore knocked down acetyl-CoA carboxylase 1 (ACC1, encoded by Acaca), which catalyzes production of malonyl-CoA from acetyl-CoA to provide building blocks for FASN (Fig. 3B) , together with cerulenin treatment. Knockdown of Acaca led to a striking reduction in cerulenin-and GSK2194069-induced toxicity ( Fig. 3C and   S2A-B ). Conversely, we tested the effect and knockdown of malonyl-CoA decarboxylase (MCD, encoded by Mlycd) which catalyzes the conversion of malonyl-CoA back to acetyl-CoA (38) .
Mlycd knockdown increased the sensitivity of both cell lines to cerulenin and GSK2194069 ( Fig.   3D and S2C ). Chemical inactivation of ACC1 by 5-(tetradecyloxy)-2-furoic acid (TOFA) had a similar effect as Acaca knockdown (Fig. 3E) (Fig. 4A and S3) . Importantly, reintroduction of Merlin in SC4-9 cells decreased levels of these proteins and restored phosphorylation of ACC ( Fig. 4B and S4) .
Consistent with the immunoblot data, quantitative PCR also showed significantly higher expression of lipogenesis-related genes in Nf2 -/-MEFs relative to Nf2 f/f MEFs (p < 0.001 for all the genes studied) (Fig. 4C) . The same trend was observed in SC4-9 cells compared to SC4-9-merlin cells (Fig. 4C) . Such an increase, especially of transcription factors SREBP1 and Lipin1, is consistent with our idea of upregulated lipid metabolism in Nf2-deficient cells. The modest effect of 5-iodotubercidin on Nf2 -/-cells (Fig. 3F) is consistent with the low phosphorylation, and thus high activity, of ACC in these cells (Fig. 4A ). Fig. 4D shows additional lipogenic enzyme roles in the fatty acid synthesis. Fasn and Acaca expression is controlled mainly by the transcription factor Sterol regulatory element binding protein 1 (SREBP1) (40, 41) , and Lipin1 is a major expression regulator of the rest of lipogenic enzymes (42, 43) . (Fig. 5B ). Immunoblot confirmed a drop in a triglyceride synthesis regulator Lipin1 and a FASN positive regulator SREBP1 protein levels caused by a decrease of MTOR phosphorylation at serine 2448 (Fig. 5B) . The same effect was observed for
Torc1 signaling is essential for fatty acid synthesis regulation. It has been previously shown that Merlin inhibits MTOR (44). MTOR is a known metabolic sensor and has been shown to regulate SREBP1 (45) and Lipin1 (46). We hypothesized that activated MTOR in
RNAi knockdown of Mtor and TORC1 component Rptor, but not TORC2 component Rictor (Fig. 5C and S5A-B) . Thus, a key event causing fatty acid synthesis upregulation in Nf2-deficient cells is TORC1 activation in the absence of Merlin.
Discussion
In this study, we show that cerulenin, an inhibitor of fatty acid synthesis is selectively toxic in cell lines lacking Merlin expression. Cerulenin has activity as an anti-obesity agent (21, 47) , but has also shown in vitro efficacy against the proliferation of colon (22), breast (48) Inhibitors such as cerulenin have also shown to have efficacy in a number of non-NF2 related cancer cell types in vitro and in preclinical models (24) . In some cases, it has been proposed that these effects are mediated by targets other than FASN. For example, cerulenin induces apoptosis in melan-a cells, but these effects appear to be independent of Fasn inhibition, and are instead thought to be mediated by an oxidative stress-associated mechanism that ultimately results in mitochondrial dysfunction (51) . FASN inhibitors have also been shown to affect the activity level of the HER2/PI3K/AKT signaling pathway in U2OS cells (52) . However, in our studies in the setting of Merlin deficiency, similar cellular and metabolic effects were seen with other three distinct small molecule FASN inhibitors as well as with Fasn siRNA. Thus, we believe that the effects of cerulenin on Merlin-null cells are related to FASN inhibition, with subsequent build-up of toxic intermediates such as malonyl-CoA, as opposed to off-target effects. This supposition is supported by the loss of cerulenin toxicity in Merlin-null cells when an ACC inhibitor is also added to the cells (Fig. 3E) .
As a clinical agent, cerulenin suffers from relatively poor bioavailability. In addition, this compound, as well as the synthetic analog C75, has undesirable side effects that include anorexia and weight loss, most likely due to effects on production of neuropeptide Y in the hypothalamus as well as activation of mitochondrial fatty acid oxidation (24, 47, 53) . In our experiments, mice tolerated treatment well, and did not experience weight loss. Still, a decrease in the FASN levels of cerulenin-treated tumours indicates that the drug reached its target in the in vivo studies.
Unfortunately, the quality of antibodies against lipogenic enzymes did not allow to confirm their While our findings suggest that upregulated fatty acid synthesis is a key element in cerulenin selectivity against Nf2-deficient cell lines, we also found other metabolic changes that might be useful in designing targeted therapies. For example, we found a significant increase in mitochondrial respiration rate and a drop in glycolysis metabolites in both FH912 (Nf2 This supposition is also indirectly confirmed by the decrease in fatty acid oxidation gene expression in Nf2-deficient cells (Fig. S7) . Additionally, we noted a profound drop in amino acid levels, especially in glutamate metabolites, dipeptide, and polypeptide levels in Nf2-null cells (Table S2) . Such a general decrease in amino acid and peptide levels might indicate an increased demand of building blocks for protein synthesis, which is likely related to the increased growth rate of Nf2-deficient cells. Similarly, a drop in glutamine level might be evidence of increased glutaminolysis supporting an increased energy demand. It is also of potential interest that Nf2-deficient cells showed an increased level of coenzymes (Table S1 ). This change specifically affected pantothenate and phosphopantetheine levels, and NAD + and NADH levels. Pantothenate and phosphopantetheine are essential for coenzyme A synthesis, and elevation of their levels is an indication of higher lipid, carbohydrate, and amino acid metabolism rates (56) . Such an increase in NAD + and NADH levels is likely necessary to support greater energy metabolism in
Nf2-deficient cells.
In summary, we have shown for the first time that Nf2-deficiency is associated with a profound reprogramming of cellular metabolism, favoring biosynthetic processes and limiting catalytic processes, and that this altered metabolism might be exploited therapeutically. In particular, the increased dependence of Nf2-deficient cells on lipid synthesis suggests that Fasn inhibitors, alone or in combination with other agents that increase malonyl-CoA levels, might be useful in treating NF2-related diseases. 
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